ASIRI HOSPITAL HOLDINGS PLC

PROVISIONAL ACCOUNTS FOR THE PERIOD ENDED
31st March 2026

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Year Ended 31 March 2026

	GROUP		COMPANY	
	31-Mar-26	**31-Mar-25**	**31-Mar-26**	**31-Mar-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Audited**	**Un-audited**	**Audited**
Revenue	**35,064,051,592**	31,022,098,797	**15,712,084,345**	13,389,481,150
Cost of Services	**(17,312,690,327)**	(16,314,757,503)	**(7,276,811,414)**	(6,678,921,582)
Gross Profit	**17,751,361,265**	14,707,341,294	**8,435,272,931**	6,710,559,568
Other Income	**304,104,403**	249,658,090	**178,062,350**	1,597,689,509
Administrative Expenses	**(9,388,657,578)**	(9,612,060,502)	**(3,802,095,619)**	(3,578,118,318)
Selling and Distribution Expenses	**(978,656,035)**	(944,781,162)	**(500,549,458)**	(450,938,130)
Finance Costs	**(1,916,755,135)**	(2,006,537,556)	**(1,641,394,287)**	(1,588,068,263)
Finance Income	**1,563,180,016**	1,258,637,974	**577,120,863**	237,447,144
Profit Before Tax	**7,334,576,936**	3,652,258,139	**3,246,416,781**	2,928,571,511
Tax Expense	**(2,162,157,868)**	(1,826,324,608)	**(933,314,859)**	(606,264,072)
Profit for the Period	**5,172,419,068**	1,825,933,530	**2,313,101,922**	2,322,307,439
Attributable to:				
Equity Holders of the Parent Company	**4,866,749,546**	1,643,691,897		
Non-Controlling Interest	**305,669,522**	182,241,633		
	5,172,419,068	1,825,933,530		
Earnings Per Share- Basic	**4.28**	1.44	**2.03**	2.04
Dividend Per Share- Ordinary Shares	**0.00**	1.50	**0.00**	1.50

STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended 31 March 2026

	Group		Company	
	31-Mar-26	**31-Mar-25**	**31-Mar-26**	**31-Mar-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Audited**	**Un-audited**	**Audited**
Profit for the Period	**5,172,419,068**	1,825,933,530	**2,313,101,922**	2,322,307,439
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net (Loss)/Gain on investment in Digital Health shares at Fair Value Through Other Comprehensive Income	-	27,200,837	-	27,200,837
Net gain/(loss) on Equity investment at Fair Value Through Other Comprehensive Income	-	12,615,325	-	-
Net gain/(loss) on subsidiary valuation at FVTOCI	-	-	-	(712,877,061)
Revaluation on land & buildings	-	1,531,111,615	-	798,028,253
Acturial gain/ (loss) on post employment benefit liability	-	(5,339,741)	-	(28,684,679)
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:	-	1,565,588,036	-	83,667,350
Tax on other comprehensive income	-	(404,995,197)	-	556,262,638
Other Comprehensive Income for the Period, Net of Tax	-	1,160,592,839	-	639,929,988
Total Comprehensive Income for the Period, Net of Tax	**5,172,419,068**	2,986,526,369	**2,313,101,922**	2,962,237,427
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent Company	**4,866,749,546**	2,776,532,152		
Non-Controlling Interest	**305,669,522**	209,994,218		
	5,172,419,068	2,986,526,369		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Three Months Ended 31 March 2026

	GROUP		COMPANY	
	31-Mar-26	**31-Mar-25**	**31-Mar-26**	**31-Mar-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**8,959,390,684**	8,242,108,152	**3,938,200,746**	3,617,877,583
Cost of Services	**(4,420,999,001)**	(4,126,850,760)	**(1,838,873,738)**	(1,722,230,903)
Gross Profit	**4,538,391,683**	4,115,257,392	**2,099,327,009**	1,895,646,680
Other Income	**73,301,798**	20,655,700	**43,727,019**	37,238,544
Administrative Expenses	**(2,370,273,389)**	(3,266,475,701)	**(927,267,188)**	(995,572,969)
Selling and Distribution Expenses	**(266,148,252)**	(279,094,506)	**(116,992,645)**	(110,561,258)
Finance Costs	**(472,203,127)**	(512,228,045)	**(425,671,697)**	(401,521,448)
Finance Income	**613,147,670**	560,471,792	**244,451,607**	150,276,260
Profit Before Tax	**2,116,216,383**	638,586,633	**917,574,105**	575,505,809
Tax Expense	**(619,167,837)**	(520,586,666)	**(258,083,275)**	(214,264,072)
Profit for the Period	**1,497,048,546**	117,999,967	**659,490,831**	361,241,737
Attributable to:				
Equity Holders of the Parent Company	**1,424,426,957**	114,463,497		
Non-Controlling Interests	**72,621,589**	3,536,469		
	1,497,048,546	117,999,967		
Earnings Per Share - Basic	**1.25**	0.10	**0.58**	0.32
Dividend Per Share - Ordinary Shares	**0.00**	1.50	**0.00**	1.50

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended 31 March 2026

	Group		Company	
	31-Mar-26	**31-Mar-25**	**31-Mar-26**	**31-Mar-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Profit for the Period	**1,497,048,546**	117,999,967	**659,490,831**	361,241,737
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net (Loss)/Gain on investment in Digital Health shares at Fair Value Through Other Comprehensive Income	-	27,200,837	-	27,200,837
Net gain/(loss) on Equity investment at Fair Value Through Other Comprehensive Income	-	12,615,325	-	-
Net gain/(loss) on subsidiary valuation at FVTOCI				(712,877,061)
Revaluation on land & buildings	-	1,531,111,615	-	798,028,253
Acturial gain/ (loss) on post employment benefit liability	-	(5,339,741)	-	(28,684,679)
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:	-	1,565,588,036	-	83,667,349
Tax on other comprehensive income	-	(404,995,197)	-	556,262,638
Other Comprehensive Income for the Period, Net of Tax	-	1,160,592,839	-	639,929,988
Total Comprehensive Income for the Period, Net of Tax	**1,497,048,546**	1,278,592,806	**659,490,831**	1,001,171,724
Attributable to:				
Equity Holders of the Parent Company	**1,424,426,957**	1,247,303,752		
Non-Controlling Interests	**72,621,589**	31,289,054		
	1,497,048,546	1,278,592,806		

STATEMENT OF FINANCIAL POSITION

	GROUP		COMPANY	
	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
	Rs.	Rs.	Rs.	Rs.
ASSETS	Un-audited	Audited	Un-audited	Audited
Non-current Assets				
Property, Plant and Equipment	**34,787,168,302**	35,261,736,339	**14,512,372,009**	14,971,249,009
Right of Use Assets	**1,322,413,115**	1,256,323,838	**1,038,572,633**	974,416,665
Goodwill	**609,654,071**	609,654,071	-	-
Investment in Subsidiaries	-	-	**41,413,818,162**	41,413,042,530
Loans granted to Related Parties	**7,990,496,977**	7,193,473,966	-	20,060,242
Other Non Current Assets	**93,876,643**	70,409,812	**67,894,643**	44,427,812
Other Non-Current Financial Assets	**57,200,837**	57,200,837	**57,200,837**	57,200,837
	44,860,809,946	44,448,798,863	**57,089,858,284**	57,480,397,095
Current Assets				
Inventories	**1,362,231,712**	974,246,361	**611,133,246**	464,971,134
Trade and Other Receivables	**3,229,267,808**	2,024,541,810	**3,853,193,657**	2,124,360,551
Loans Granted to Related Parties	**2,839,107,779**	1,272,976,210	**3,185,416,805**	1,483,771,765
Other Current Assets	**7,498,564,971**	5,436,222,728	**2,520,609,951**	2,008,341,810
Cash and Cash Equivalents	**919,011,919**	654,099,154	**120,239,443**	166,359,209
	15,848,184,189	10,362,086,264	**10,290,593,102**	6,247,804,469
Total Assets	**60,708,994,138**	54,810,885,128	**67,380,451,387**	63,728,201,565
EQUITY AND LIABILITIES				
Capital and Reserves				
Stated Capital	**4,748,108,334**	4,748,108,334	**4,748,108,334**	4,748,108,334
Other Components of Equity	**10,791,524,071**	10,791,493,075	**27,625,138,125**	27,625,138,125
Retained Earnings	**8,991,677,265**	4,124,927,719	**3,937,928,932**	1,624,827,010
Share Holders' Fund	**24,531,309,670**	19,664,529,129	**36,311,175,391**	33,998,073,469
Non-Controlling Interests	**2,072,644,888**	1,767,782,128	-	-
Total Equity	**26,603,954,558**	21,432,311,256	**36,311,175,391**	33,998,073,469
Non-current Liabilities				
Interest Bearing Loans and Borrowings	**5,061,471,054**	5,883,031,653	**7,759,761,935**	8,086,362,206
Deferred Tax Liabilities	**5,979,960,944**	5,606,880,493	**9,081,074,408**	8,719,827,008
Employee Benefit Liability	**917,568,394**	868,652,335	**356,514,985**	361,069,127
	11,959,000,392	12,358,564,481	**17,197,351,328**	17,167,258,341
Current Liabilities				
Trade and Other Payables	**6,419,283,369**	5,807,620,711	**3,287,378,832**	2,564,842,783
Dividend Payable	**93,788,980**	75,761,221	**77,691,781**	61,359,499
Interest Bearing Loans and Borrowings	**8,778,943,027**	9,241,526,850	**7,170,764,880**	6,676,601,479
Income Tax Payable	**2,683,020,240**	1,619,176,869	**858,470,538**	316,564,446
Bank Overdraft	**4,171,003,572**	4,275,923,740	**2,477,618,638**	2,943,501,547
	22,146,039,188	21,020,009,391	**13,871,924,668**	12,562,869,753
Total Equity and Liabilities	**60,708,994,138**	54,810,885,128	**67,380,451,387**	63,728,201,565
Net Assets Per Share	21.57	17.29	31.92	29.89

The above figures are provisional & subject to audit.
It is certified that the Financial Statements have been prepared in accordance with the requirements of the Companies Act No.7 of 2007.

-sgd-
S L R Piyal
Director Finance

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board.

-sgd-
Ashok Pathirage
Chairman / Managing Director

-sgd-
Haresh Kaimal
Director

30 April 2026
Colombo

STATEMENT OF CHANGES IN EQUITY
For the Year Ended 31 March 2026

GROUP

	Equity Attributable to Equity Holders of the Parent							
	Stated Capital	**Revaluation Reserve**	**Reserve on Consolidation**	**Retained Earnings**	**Fair Value Reserve of Financial Assets at FVOCI**	**Foreign Currency Translation Reserve**	**Minority Interest**	**Total**
	Rs.	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**	**Rs.**
Balance as at 01 April 2024	**4,748,108,334**	**10,592,574,929**	**(919,511,358)**	**4,274,170,578**	**(101,877,871)**	**823,404**	**1,602,044,861**	**20,196,332,877**
Profit for the Period	-	-	-	1,645,991,930	-	(2,300,033)	182,241,633	1,825,933,530
Other Comprehensive Income	-	1,100,856,188	-	2,574,781	29,409,285	-	27,752,585	1,160,592,839
Total Comprehensive Income	**-**	**1,100,856,188**	**-**	**1,648,566,711**	**29,409,285**	**(2,300,033)**	**209,994,218**	**2,986,526,369**
Acquisition of Non- controlling interests	-	-	9,358	-	-	-	(448,292)	(438,934)
Interim dividends 2025/26	-	-	-	(1,706,300,394)	-	-	-	(1,706,300,394)
Subsidiaries dividend to minority shareholders	-	-	-	-	-	-	(43,808,658)	(43,808,658)
Equity Investments at FVOCI reclassified to Retained Earnings	-	-	-	(91,509,172)	91,509,172	-	-	-
Balance as at 31 March 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**4,124,927,719**	**19,040,586**	**(1,476,628)**	**1,767,782,128**	**21,432,311,256**
Balance as at 01 April 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**4,124,927,719**	**19,040,586**	**(1,476,628)**	**1,767,782,128**	**21,432,311,256**
Profit for the Period	-	-	-	4,866,749,546	-	-	305,669,522	5,172,419,068
Other Comprehensive Income	-	-	-	-	-	-	-	-
Total Comprehensive Income	**-**	**-**	**-**	**4,866,749,546**	**-**	**-**	**305,669,522**	**5,172,419,068**
Acquisition of Non-Controlling Interest	-	-	30,996		-	-	(806,762)	(775,766)
Balance as at 31 March 2026	**4,748,108,334**	**11,693,431,117**	**(919,471,004)**	**8,991,677,265**	**19,040,586**	**(1,476,628)**	**2,072,644,888**	**26,603,954,558**

COMPANY

	Stated Capital	**Revaluation Reserve**	**Fair Value Reserve of Financial Assets at FVOCI**	**Retained Earnings**	**Total**
	Rs.	**Rs.**	**Rs.**	**Rs.**	**Rs.**
Balance as at 01 April 2024	**4,748,108,334**	**3,943,767,585**	**23,021,361,277**	**1,028,899,241**	**32,742,136,437**
Profit for the Period	-	-	-	2,322,307,439	2,322,307,439
Other Comprehensive Income	-	558,619,777	101,389,486	(20,079,276)	639,929,988
Total Comprehensive Income	-	558,619,777	101,389,486	2,302,228,163	2,962,237,427
Interim dividends 2025/26	-	-	-	(1,706,300,394)	(1,706,300,394)
Balance as at 31 March 2025	**4,748,108,334**	**4,502,387,362**	**23,122,750,763**	**1,624,827,011**	**33,998,073,469**
Balance as at 01 April 2025	**4,748,108,334**	**4,502,387,362**	**23,122,750,763**	**1,624,827,010**	**33,998,073,469**
Profit for the Period	-	-	-	2,313,101,922	2,313,101,922
Other Comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	2,313,101,922	2,313,101,922
Balance as at 31 March 2026	**4,748,108,334**	**4,502,387,362**	**23,122,750,763**	**3,937,928,932**	**36,311,175,391**

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF CASH FLOWS
For the Year Ended 31 March

	GROUP		COMPANY	
	31-Mar-26 Rs. Un-audited	31-Mar-25 Rs. Audited	31-Mar-26 Rs. Un-audited	31-Mar-25 Rs. Audited
Cash Flows from/(used in) Operating Activities				
Profit Before Tax Expense	**7,334,576,936**	3,652,258,139	**3,246,416,781**	2,928,571,510
Adjustments for				
Depreciation	**1,851,337,942**	1,775,879,408	**779,121,873**	747,960,152
Amortization of Leasehold Assets	**217,819,067**	193,078,937	**148,723,226**	134,941,029
Loss/(Profit) on Disposal of Property, Plant and Equipment	**(13,525,107)**	2,224,079	**(12,425,585)**	2,215,143
Loss/(Gain) on share disposal	-	(457,135)	-	-
Script Dividend Income	-	(14,442,348)	-	-
Derecognition of ROU asset & liability	**(12,538,390)**	-	**(11,988,103)**	-
Provision for Bad and Doubtful Debts	**38,227,027**	102,917,832	**13,606,078**	27,992,892
Provision for impairment	-	1,369,187,044	-	245,171,037
Provision for Retirement Gratuity	**219,776,844**	184,886,992	**87,667,357**	76,706,885
Unrealized Foreign Currency Exchange Gain	**(5,361,683)**	(7,204,890)	**(3,535,229)**	(451,189)
Dividend Income	-	-	-	(1,454,408,073)
Finance Costs	**1,916,755,135**	2,006,537,556	**1,641,394,287**	1,588,068,263
Income from Investments	**(1,563,180,016)**	(1,258,637,974)	**(577,120,863)**	(237,447,144)
Operating Profit Before Working Capital Changes	**9,983,887,755**	8,006,227,639	**5,311,859,822**	4,059,320,505
Changes in Working Capital				
(Increase)/Decrease in Inventories	**(387,985,351)**	307,795,526	**(146,162,112)**	101,536,399
(Increase)/ Decrease in Other Current Assets	**(1,965,934,860)**	(4,758,485,364)	**(812,775,847)**	(1,757,222,361)
(Increase)/ Decrease in Trade and Other Receivables	**(1,143,032,140)**	(164,731,804)	**(1,742,439,184)**	(926,666,331)
(Decrease)/Increase in Trade and Other Payables	**611,662,660**	1,870,766,860	**722,536,049**	952,593,006
Cash Generated from Operations	**7,098,598,065**	5,261,572,858	**3,333,018,728**	2,429,561,218
Income Tax paid	**(728,404,260)**	(1,083,263,038)	**(30,000,000)**	(30,000,000)
Finance Costs paid	**(1,521,571,618)**	(1,472,999,226)	**(832,126,144)**	(1,077,250,701)
Defined Benefit Plan Costs paid	**(170,860,783)**	(106,731,032)	**(92,221,500)**	(49,059,766)
Net Cash from Operating Activities	**4,677,761,403**	2,598,579,561	**2,378,671,084**	1,273,250,751
Cash Flows from/(used in) Investing Activities				
Acquisition of Property, Plant and Equipment	**(1,396,160,273)**	(1,581,321,804)	**(333,915,617)**	(476,473,585)
Acquisition of Right of use assets	**(2,085,088)**	(33,313,034)	**(2,085,088)**	716,198
Increase in Interest in Subsidiaries	-	-	**(775,766)**	(438,934)
(Increase)/ Decrease in Loans Granted to Related Parties	**(1,000,000,000)**	(1,254,180,993)	**(940,000,000)**	(1,256,066,986)
Proceed from/(repayment of) Loans Obtained From Related Parties	**61,000,000**	-	-	(335,750,850)
Cash received from Sale of shares	-	287,012,765	-	-
Proceeds from Disposal of Property, Plant and Equipment	**32,914,988**	24,399,481	**26,096,248**	3,154,435
Income From Investments	**66,687,669**	83,932,579	**63,517,085**	922,082
Net Cash used in Investing Activities	**(2,237,642,705)**	(2,473,471,006)	**(1,187,163,139)**	(2,063,937,641)
Cash Flows from/(used in) Financing Activities				
Dividends Paid	-	(766,190,196)	-	(766,190,196)
Dividends Paid to Minority Shareholders	-	(37,237,360)	-	-
Reversal of unclaimed dividends	**18,027,759**	-	**16,332,282**	-
Acquisition of Non Controlling Interests	**(775,766)**	(438,934)	-	-
Net Proceeds/(Net Repayments) from External Borrowings	**(1,827,049,423)**	635,049,567	**(608,652,073)**	1,623,748,991
Repayment of Lease Obligations	**(260,488,336)**	(300,757,815)	**(179,425,013)**	(186,468,842)
Net Cash from/(used in) Financing Activities	**(2,070,285,766)**	(469,574,737)	**(771,744,803)**	671,089,953
Net Increase/(Decrease) in Cash and Cash Equivalents	**369,832,933**	(344,466,182)	**419,763,143**	(119,596,937)
Cash and Cash Equivalents at the Beginning of the Year	**(3,621,824,586)**	(3,277,358,404)	**(2,777,142,338)**	(2,657,545,401)
Cash and Cash Equivalents at the End of the Year	**(3,251,991,653)**	(3,621,824,586)	**(2,357,379,195)**	(2,777,142,338)
Analysis of Cash and Cash Equivalents				
Favorable Balances				
Cash in Hand and at Bank	**919,011,919**	654,099,154	**120,239,443**	166,359,209
Unfavorable Balances				
Bank Overdrafts	**(4,171,003,572)**	(4,275,923,740)	**(2,477,618,638)**	(2,943,501,547)
Cash and Cash Equivalents	**(3,251,991,653)**	(3,621,824,586)	**(2,357,379,195)**	(2,777,142,338)

NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the Period Ended 31 March 2026

1. Corporate Information
1.1 General
Asiri Hospital Holdings PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 181, Kirula Road, Colombo 5.

1.2 Date of Authorisation for Issue
The Interim Condensed Financial Statements of the Group and the Company for the period ended 31 March 2026 were authorised for issue by the Board of Directors on 30 April 2026.

2. Basis of Preparation
The Interim Condensed Financial Statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange.

3. Accounting Policies
The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2025 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

Group

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd ,Softlogic Super market (Pvt) Ltd, Softlogic Retail (Pvt) Ltd, Softlogic Communication Services (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

Company

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd and Softlogic Super Market (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities
A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments from 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during that period. The Company has filed appeals against these assessments in the Court of Appeal and the cases are on going

We also have filed an appeal in the Supreme Court(vide Supreme Court Special Leave To APPEAL APP: SC/SPL/LA 69/2026] against the Judgment of the Court of Appeal dated 19th January 2026 relating to the Writ application (CA (Writ) 386/ 2016 which was filed by the Company to prevent seizure of bank accounts of the Company as part of IRD's recovery actions .

Since there are litigations, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2025.

4.3 Capital Expenditure Commitments
There were no material commitments outstanding as at 31 March 2026 for future capital expenditure except for below;
Rs.21,901,554 contracted with suppliers for the construction of Asiri Hospital Kandy (Rs.21,901,554 as at 31 March 2025).

4.4 Comparative Information
Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Events Occurring After the Reporting Period
There were no material events that occurred after the reporting date that require adjustments or disclosure to the Financial Statements.

NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the Period Ended 31 March 2026

5. Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue
- Other revenue includes income generated from healthcare professional services provided by Asiri Academy of Health Sciences (Pvt) Ltd.

Segment	Group		Company	
	2026	2025	2026	2025
	Rs.	Rs.	Rs.	Rs.
Pre Care	15,596,865,678	16,588,348,030	8,961,784,724	7,850,017,444
Post Care	16,992,207,062	12,340,057,394	5,838,635,663	4,617,054,133
Pharmaceutical	2,405,285,967	2,043,260,861	911,663,958	922,409,571
Other services	69,692,886	50,432,512		
	35,064,051,592	31,022,098,797	15,712,084,345	13,389,481,148

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Hospital Holdings PLC is as follows:

	Quarter to 31-Mar-26	Quarter to 31-Mar-25
Highest Price per Share (Rs.)	37.00	27.20
Lowest Price per Share (Rs.)	29.00	24.60
Last Traded Price per Share (Rs.)	30.80	25.80

No of Shares Representing Stated Capital	As at 31-Mar-26	As at 31-Mar-25
No of Ordinary Shares	1,137,533,596	1,137,533,596

* Earnings and net assets per share are based on 1,137,533,596 shares in issue as at 31 March 2026.

Statement of Shareholding of Directors Name of Director	As at 31-Mar-26	As at 31-Mar-25
Mr. A. K. Pathirage	371,664	371,664
Mr. Rajaratnam Selvaskadan	-	-
Mr. Vishal Bali	-	-
Mr. A. N. Thadani	-	-
Mr. H K Kaimal	-	-
Mr. Govinda Waduge Don Hemantha Udaya Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. M.I. Furkan	-	-
Mr. Galle Dodanduwage Kalum Lakmal De Silva	-	-

Major Shareholdings Twenty Largest Shareholders	As at 31-Mar-26	%	As at 31-Mar-25	%
Softlogic Holdings PLC	627,025,050	55.12	627,025,050	55.12
Merrill Lynch Pierce Fenner & Smith-Tpg Growth Iii Sf Pte Ltd	328,258,328	28.86	328,258,328	28.86
BBH-Tundra Sustainable Frontier Fund	30,000,000	2.64	30,000,000	2.64
Softlogic Life Insurance PLC-A/C No. 04 (Participating Fund)	9,000,000	0.79	9,000,000	0.79
Sri Lanka Insurance Corporation Ltd-Life Fund	7,851,792	0.69	7,851,792	0.69
Mr. Pujitha Punsiri Subasinghe	7,510,340	0.66	7,531,586	0.66
J.B. Cocoshell (Pvt) Ltd	7,474,489	0.66	3,360,860	0.30
Softlogic Life Insurance PLC-A/C No. 05 (Non-Participating Fund)	5,956,877	0.52	5,956,877	0.52
Employees Trust Fund Board	4,245,693	0.37	4,245,693	0.37
Deutsche Bank Ag As Trustee For Jb Vantage Value Equity Fund	4,077,605	0.36	5,086,406	0.45
Dr. Welagedara Mudiyanselage Swarnamali Welagedara	3,375,000	0.30	3,375,000	0.30
Mr. Hewa Komanage Jayantha Dharmadasa	2,826,650	0.25	2,908,650	0.26
Dr. Luhubanduwaduge Don Abo Claudius Luvis	2,557,423	0.22	2,741,720	0.24
Mr. Mohamed Faizer Hashim	2,087,160	0.18	2,087,160	0.18
Sampath Bank PLC/Yaden Capital (Private) Limited	1,800,000	0.16	-	0.00
Miss Theja Thushari Weerasinghe	1,746,630	0.15	1,746,630	0.15
Jafferjee Brothers Exports (Private)Limited	1,616,000	0.14	3,487,500	0.31
Sri Lanka Insurance Corporation Ltd-General Fund	1,557,417	0.14	2,807,417	0.25
Mr. Uditha Harilal Palihakkara	1,465,450	0.13	1,424,268	0.13
Mrs. Laxmi Leela Jayasekera	1,199,297	0.11	1,199,297	0.11
	1,051,631,201	92.45	1,050,094,234	92.31
Shares held by the Balance Shareholdings	85,902,395	7.55	87,439,362	7.69
Total Issued Shares	1,137,533,596	100.00	1,137,533,596	100.00
Public Shareholding	166,921,677	14.67	166,921,677	14.67
Total Number of Public Shareholders	6,545		5,698	

The Float- adjusted market capitalization as at 31st March 2026 is Rs.5,123,098,680.97 and the Company is in compliance with option 3 of the CSE Listing Rules 7.13.1 (i) (a) which requires 7.5 % minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Hospital Holdings PLC

Registered Office
181, Kirula Road, Colombo 05,
Sri Lanka.

Office & Administrative Complex
Asiri Surgical Hospital PLC
21, Kirimandala Mawatha,
Colombo 05, Sri Lanka.
Telephone: 011 4524400
Email: info@asiri.lk
Web: www.asirihealth.com

Company Registration Number
PQ204

Legal Form
A quoted public company incorporated in Sri Lanka on 29 September 1980, under the Companies Act No.17 of 1982, with limited liability.Re-registered on 30 September 2008 under the Companies Act No. 07 of 2007.

Stock Exchange Listing
The Ordinary Shares of the Company have been listed with the Colombo Stock Exchange since June 1986.

Board of Directors
Mr. A. K. Pathirage - Chairman/Managing Director
Mr. G. W.D.H. U. Gunawardena
Mr. Rajaratnam Selvaskandan
Mr. H K Kaimal
Mr.V. Bali
Mr. A. N. Thadani
Mr. S. Shapira
Mr. M.I. Furkan
Mr. G.D.K.L.De Silva

Audit Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Nomination and Governance Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr.V. Bali
Independent Non-Executive Director

Frequency of Meetings
Committee meets once each year or as required.

Related Party Transactions Review Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Subsidiary Companies
Central Hospital Ltd
114, Norris Canal Road, Colombo 10.

Asiri Central Hospitals Ltd
114, Norris Canal Road, Colombo 10.

Asiri Surgical Hospital PLC
21, Kirimandala Mawatha, Colombo 5.

Asiri Diagnostics Services (Pvt) Ltd
181, Kirula Road, Colombo 05.

Asiri Hospital Matara (Pvt) Ltd
26, Esplanade Road, Uyanwatte,
Matara.

Asiri Laboratories (Pvt) Ltd
181, Kirula Road, Colombo 5.

Asiri Hospital Galle (Pvt) Ltd
10, Wackwella Road, Galle.

Asiri AOI Cancer Centre (Pvt) Ltd
21, Kirimandala Mawatha, Colombo 5.

Asiri Port City Hospital (Pvt) Ltd.
14, De Fonseka Place, Colombo 5.

Asiri Academy of Health Sciences (Pvt) Ltd.
181, Kirula Road, Colombo 5.

Asiri Diagnostics Services (Asia) Pte Limited
8, Temasek Boulevard, # 35-03 Suntec Tower 3.
Singapore.

Auditors
Messrs. Ernst & Young
(Chartered Accountants)
109, Galle Road,
Colombo 03.

Secretaries
Messrs. Softlogic Corporate Services (Pvt) Ltd
14, De Fonseka Place, Colombo 5.

Stock Code
ASIR.N0000

Bankers
Commercial Bank of Ceylon PLC
Sampath Bank PLC
Nations Trust Bank PLC
Hatton National Bank PLC
Cargills Bank Limited
Bank of Ceylon PLC
National Development Bank PLC
Seylan Bank PLC
DFCC Bank PLC
Union Bank of Colombo PLC